Diagnostic, Pathologic, and Therapeutic Considerations for Primary CNS Lymphoma

Research output: Contribution to journalArticlepeer-review


Primary CNS lymphoma (PCNSL) is a rare lymphoma representing 3% of CNS malignancies. The diagnosis is complicated by the unique risks associated with brain biopsy, and the treatment is similarly complicated by the restriction of effective therapeutics able to cross the blood-brain barrier. Currently, the majority of individuals diagnosed with this disease are immunocompetent although immune deficiency related to HIV or immunosuppressive therapy remains an important risk factor. Improvements in both frontline therapy and consolidation options, including the use of hematopoietic stem-cell transplantation, have translated to improved survival. Unfortunately, patients experiencing relapsed or refractory disease often fare poorly. Here, we review key clinical, pathologic, and therapeutic aspects of PCNSL and highlight challenging clinical scenarios that may be encountered by the treating oncologist.

Original languageEnglish (US)
Pages (from-to)195-202
Number of pages8
JournalJCO Oncology Practice
Issue number2
StatePublished - Feb 1 2024

ASJC Scopus subject areas

  • Oncology
  • Health Policy
  • Oncology(nursing)


Dive into the research topics of 'Diagnostic, Pathologic, and Therapeutic Considerations for Primary CNS Lymphoma'. Together they form a unique fingerprint.

Cite this